The Oncology Institute, Inc.
TOI
$0.716
$0.09114.56%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Net Income | 7.50% | 8.39% | 33.70% | -70.38% | -551.42% |
Total Depreciation and Amortization | -7.36% | 14.22% | 17.34% | 32.30% | 49.74% |
Total Amortization of Deferred Charges | 1.34% | 1.36% | 2.36% | 1.29% | 75.56% |
Total Other Non-Cash Items | -66.81% | -96.01% | -77.68% | 1,120.54% | 157.25% |
Change in Net Operating Assets | 1,131.77% | -289.12% | 42.81% | 223.53% | 85.38% |
Cash from Operations | 109.86% | -80.83% | -2.79% | 72.19% | 59.26% |
Capital Expenditure | 143.23% | -94.88% | 66.83% | 56.84% | 21.85% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | 66.81% | -100.00% |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 15.75% | -33.64% | -1.20% | 142.00% | 109.88% |
Cash from Investing | 34.93% | -27.01% | 5.36% | 135.70% | 108.78% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -61.38% | 99.34% | 22.23% | 34.79% | 3.97% |
Issuance of Common Stock | -100.00% | -- | -- | -74.43% | -83.54% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 61.56% | -511.43% | -- | -62.96% | 55.12% |
Cash from Financing | 67.86% | 17.45% | 45.11% | -110.27% | -100.72% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 908.99% | -97.30% | 107.02% | 112.56% | 51.24% |